Literature DB >> 9292127

Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia.

V J Lund1, D J Howard.   

Abstract

From a cohort of 35 patients with hereditary haemorrhagic telangiectasia (HHT), 12 patients have undergone closure of the one or both nasal cavities during the last three years for refractory epistaxis. All had failed other forms of treatment including hormone therapy, laser coagulation and septodermoplasty. All patients were available for follow-up at six months or longer. In all patients where complete closure was achieved (11 out of 12) bleeding ceased completely from the operated side.

Entities:  

Mesh:

Year:  1997        PMID: 9292127     DOI: 10.1017/s0022215100136369

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  11 in total

1.  First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT).

Authors:  Basel Al Kadah; George Papaspyrou; Mathias Schneider; Bernhard Schick
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-23       Impact factor: 2.503

2.  Treatment of severe refractory epistaxis in hereditary hemorrhagic telangiectasia using a two-flap nasal closure method.

Authors:  Benjamin H Timmins; Benjamin N Hunter; Kevin F Wilson; P Daniel Ward
Journal:  Int Forum Allergy Rhinol       Date:  2016-01-11       Impact factor: 3.858

3.  Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).

Authors:  Kornelia E C Wirsching; Frank Haubner; Thomas S Kühnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-01-09       Impact factor: 2.503

Review 4.  Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.

Authors:  Arash Abiri; Khodayar Goshtasbi; Marlon Maducdoc; Ronald Sahyouni; Marilene B Wang; Edward C Kuan
Journal:  Lasers Surg Med       Date:  2019-08-22       Impact factor: 4.025

5.  Patient-recorded benefit from nasal closure in a Danish cohort of patients with hereditary haemorrhagic telangiectasia.

Authors:  Jonas Hjelm Andersen; Anette Drøhse Kjeldsen
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-12-16       Impact factor: 2.503

6.  A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors:  C Rohrmeier; H G Sachs; T S Kuehnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-31       Impact factor: 2.503

Review 7.  Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century.

Authors:  M E Begbie; G M F Wallace; C L Shovlin
Journal:  Postgrad Med J       Date:  2003-01       Impact factor: 2.401

8.  A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab.

Authors:  Ahmad Amanzada; Gwen-Jana Töppler; Silke Cameron; Harald Schwörer; Giuliano Ramadori
Journal:  Case Rep Oncol       Date:  2010-12-11

9.  Hereditary hemorrhagic telangiectasia.

Authors:  Nagesh Kamath; Sumit Bhatia; Harneet Singh; Anurag Shetty; Shiran Shetty
Journal:  N Am J Med Sci       Date:  2015-03

Review 10.  Optimal management of hereditary hemorrhagic telangiectasia.

Authors:  Neetika Garg; Monica Khunger; Arjun Gupta; Nilay Kumar
Journal:  J Blood Med       Date:  2014-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.